In 2010

The project begins.

Relying onthe Institute of Microelectronics of Tsinghua University／Shenzhen Tsinghua University Research Institute platform.

Cooperate with China-Japan Friendship Hospital to carry out animal experiments on gastric and colon stimulators.

In 2013

Register Changzhou Rishena Medical Device Co., Ltd. Settled in Changzhou Development Zone.

Received venture capital injection from Tsinghua Science and Technology Park Venture Capital.

Obtained Longcheng Yingcai reward of 3 million yuan and equity financing.

In 2014

Built 100,000-level clean workshop.

2 products were sent for inspection by Beijing Medical Device Testing Institute.

Obtained the production license of Class III medical devices.

Won the Jiangsu Province Entrepreneurship and Innovation Talent Award.

In 2015

Obtain test reports for VNS and GES products.

Five hospitals, including Xuanwu Hospital, participated in the clinical trial of VNS products.

Won the Jiangsu Provincial Innovation Fund Award.

In 2016

Lead the National Key R&D Program project, with 10 million yuan support for implantable spinal cord stimulators implantable spinal cord stimulators.

Participants include Tsinghua University, Institute of Semiconductors, Chinese Academy of Sciences, Xuanwu Hospital, Peking University People's Hospital, and Beijing Beiqi Medical.

In 2017

Sent for testing Deep thermocoagulation electrode (SEEG).

Won the reward of 300+1.3 million yuan from the Jiangsu Province double innovation team.

Received strategic investment from Tsinghua Venture Capital and Sanjiang Capital.

In 2018

VNS is submitted for review, and SCS products are submitted for inspection.

Led by Xuanwu Hospital of Capital Medical University, 301 Hospital, Shanghai Renji, the Second Affiliated Hospital of Zhejiang University, Qilu Hospital, etc. participated in the clinical trial of deep thermocoagulation brain electrodes.

Supported by the National Key R&D Program: Key Technologies and Clinical Application Research of Neuromodulation and Intelligent Rehabilitation of Alzheimer's Disease.

In 2019

Started SCS clinical trials and obtained the National Key R&D Program project, neuromodulation treatment of depression.

Received strategic investment from Aipeng Medical and Rongan Capital.

In 2020

Obtained VNS product registration certificate and put it on sale.

SEEG products are submitted for review.

In 2021

The non-implantable earnail vagus nerve stimulator (tVNS501) was approved for marketing.

SEL-4XX series intracranial brain electrode (SEEG) was approved for marketing.

In 2022

The implantable spinal cord stimulator (SCS) was approved for marketing.

In the clinical trial study of implantable closed-loop brain stimulator (CNS) , it was the first to be used for the treatment of brain function diseases such as Parkinson's disease and epilepsy.